We read with interest the article by Gulati et al. (Opinion: The rise, fall, and possible resurrec tion of renal denervation. Nat. Rev. Cardiol. 13, 238-244; 2016) 1 . The authors discussed the results of the SYMPLICITY HTN trials and concluded that current evidence is insuffi cient to declare renal denervation a failure for the treatment of resistant hypertension. In their Perspectives article, however, they have not considered the possibility that the current theoretical basis for renal denervation therapy for resistant hypertension might be erroneous.
. However, this basis is questionable because the contribution of platelets to renal noradrenaline spillover has not been taken into account. The plate lets are an important factor that determines plasma noradrenaline levels. They collect, store, and degrade (through monoamine oxi dase) noradrenaline from plasma, but release undegraded noradrenaline during their activa tion (FIG. 1) . Given that the lifespan of platelets is around 10 days, ~10% of circulating plate lets are destroyed every day. The concentra tion of noradrenaline is substantially higher in platelets than in plasma, with a ratio of plate let to plasma concentration of 1855:1 (REF. 3 ). This ratio indicates that intraorgan platelet destruction is an important source of regional noradrenaline spillover.
Patients with hypertension have platelet abnormalities, including increased platelet vol ume and elevated platelet noradrenaline levels.
In vitro evidence has shown that a high diastolic blood pressure correlates with a rapid efflux of noradrenaline from platelets 4 , suggesting an overload of noradrenaline in patients with hypertension. Importantly, increased plate let destruction can be observed in both renal disorders and severe hypertension. The biopsy findings of renal thrombotic microangiopathy in the context of severe hypertension 5 show evidence of intrarenal platelet destruction. The increased destruction of platelets that have high levels of noradrenaline might subsequently trigger the release of more noradrenaline into the renal circulation. Moreover, hyper tension is associated with renal insufficiency, including renal disease and reduced nephron number. As shown in FIG. 1 , renal insufficiency might decrease noradrenaline clearance and thus increase the burden on platelets. Indeed, an inverse correlation between estimated glomerular filtration rate and mean platelet volume has been demonstrated 6 . Therefore, an alternative and likely explanation for the increased renal noradrenaline spillover in hypertension is attributable to a combination of renal insufficiency and increased platelet destruction, accounting for the neutral results of the SYMPLICITY HTN3 study.
Platelet overload or increased platelet vol ume can be caused by many factors, includ ing diet 7 , increased sympathetic activity 8 , and renal insufficiency 6 . Among these factors, renal sympathetic denervation has been shown in SYMPLICITY HTN3 to be ineffective for resistant hypertension, and reduced nephron number, or renal insufficiency, cannot be reversed by medication. By contrast, dietary risk factors are avoidable, and many have been identified. For example, xenobiotics and excess vitamins can disturb noradrenaline degrad ation 9, 10 . Therefore, treatment of hypertension should focus on reducing known dietary risk factors, rather than on renal denervation.
